Regenxbio Inc (RGNX) Stock Price, Quote & News

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phas...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 552 8181

Website: www.regenxbio.com

Address:

9804 Medical Center Drive, Rockville, United States

DarkOrb Jul. 31 at 8:36 PM

$RGNX Quarterly call is August 7 premarket. Call info in the link below. https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-host-conference-call-august-7-discuss-second-quarter-0

0 · Reply

maphere Jul. 31 at 5:41 PM

$CLSD $RGNX My apologies, my post below on Abbvie transcript was from earlier this year. The current transcript does not refer to Abbvie's eye programs...any of them, not just Regenxbio. https://www.investing.com/news/transcripts/earnings-call-transcript-abbvie-q2-2025-sees-stock-surge-on-earnings-beat-93CH-4164055

0 · Reply

maphere Jul. 31 at 4:30 PM

$RGNX $CLSD Abbvie comments today on the Regenxbio...kinda positive yet I don't see the DR trial starting this year based on the answer: ____________ "Your question on eye care, I mean our focus on eye care is in glaucoma, retinal disease, and prescription dry eye. It has very much a scientific focus. It's a data-driven business. It's a very efficient business as well. And obviously, we're excited about the REGENXBIO Gene Therapy Program focused on wet AMD and diabetic retinopathy. Depending on how that plays out, I think you could see that as becoming a stronger growth driver. We obviously have four of the five, as you think about, you get a lot of questions there. But we don't get as many questions on eye care, but we do believe as you start to get more visibility to this REGENXBIO Program, you'll likely spend more time focusing on it. We think of it as a potential to be a long-term growth driver for the company. And we like the fit it has for AbbVie." https://www.fool.com/earnings/call-transcripts/2025/01/31/abbvie-abbv-q4-2024-earnings-call-transcript/

1 · Reply

cold_beef_cake Jul. 30 at 7:21 PM

$RGNX Whoa, Vinay Prasad resigned from his position. Didn't realize. That was likely the reason most bios were up close to 10% at one point today.

0 · Reply

NVDAMillionaire Jul. 29 at 10:40 PM

$RGNX Brilliant piece that captures RGNX's situation perfectly. So if you want to update your understanding of RGNX or get to know RGNX better, this is essential reading. https://beyondspx.com/article/regenxbio-catalysts-aligning-for-a-gene-therapy-commercial-transition-nasdaq-rgnx

0 · Reply

maphere Jul. 29 at 7:52 PM

$CLSD $RGNX Eye spy with my little eye... https://www.linkedin.com/posts/ois-net_baruch-d-kuppermann-md-chair-of-the-department-ugcPost-7356042392753373185-s_0H?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAFbX6sB6O9p99YHD4xHsIXTcY3tswQnStc

2 · Reply

maphere Jul. 29 at 3:07 PM

$CLSD $BCRX $RGNX This week starting Tues. - Sat. is a large eye conference combo: OIS and ARSR in Longbeach Ca. (links below). CLSD is not presenting but maybe some wink-winks happen. THUR: Suprachoroidal Avoralstat, a Plasma Kallikrein Inhibitor, Stops Vascular Leakage in a Well-Established Rabbit Model (My note: does BCRX do a PR about this presentation, first of its kind for them in this niche). FRI: 1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD https://www.asrs.org/content/documents/detailed-schedule-with-running-changes_july-28.pdf Spotlight on Regenerative Therapies REGENXBIO | Steve Pakola, MD, Chief Medical Officer Part 2 – Strategic Perspectives Julian Smith, General Manager Portfolio Commercial Strategy - Eye Care - AbbVie Co-Moderated By: Ram Palanki, PharmD, Executive Vice President & Chief Commercial Officer - REGENXBIO Spotlight on Drug Delivery (panelist) Thomas Ciulla, MD, MBA, Clinical Professor of Ophthalmology https://ois.net/retina-innovation-summit-agenda/

1 · Reply

maphere Jul. 28 at 2:43 PM

$CLSD $RGNX The PH2 DR SCS trial changed status from "Recruiting" to "Active, Not Recruiting" today. https://clinicaltrials.gov/study/NCT04567550?term=abbv-rgx-314&rank=3&tab=history&a=10&b=11&compareMode=sideBySide#version-content-panel

1 · Reply

rando321456 Jul. 25 at 9:34 PM

$RGNX Is there an angle of advantage from the fact that they are demonstrating such good numbers, despite the average age at dosing is 8.7 with their functional numbers being from patients that are predominantly 8+? My feeling is that this was an under reported aspect of their data read out, these patients are some of the most challenging to treat with a gene therapy in the ambulatory population.

1 · Reply

DarkOrb Jul. 24 at 7:08 PM

$RGNX Another SRPT Elevidys update. After initially refusing the FDA’s request to stop shipment on Elevidys late last week, this week SRPT relented and halted shipment for all patients. Today it is being reported (behind a paywall) that the FDA is not going to let Elevidys back on the market without additional safety studies. RGNX has had very little discernible reaction to these developments over the past couple weeks. I would think approval is going to be more difficult for RGX-202, but I have no idea. https://x.com/ZacharyBrennan/status/1948402586144412123

3 · Reply

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

Jul 10, 2025, 11:54 AM EDT - 24 days ago

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Jun 6, 2025, 4:02 PM EDT - 2 months ago

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

Jun 5, 2025, 11:43 AM EDT - 2 months ago

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

Jun 5, 2025, 7:05 AM EDT - 2 months ago

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Jun 2, 2025, 7:05 AM EDT - 2 months ago

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

May 19, 2025, 4:05 PM EDT - 2 months ago

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 14, 2025, 7:13 AM EDT - 2 months ago

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

May 13, 2025, 7:07 AM EDT - 2 months ago

REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:05 AM EDT - 2 months ago

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

May 12, 2025, 4:05 PM EDT - 2 months ago

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

May 8, 2025, 7:05 AM EDT - 3 months ago

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

May 6, 2025, 7:05 AM EDT - 3 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

Apr 30, 2025, 4:05 PM EDT - 3 months ago

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

Mar 26, 2025, 12:31 PM EDT - 4 months ago

5 Reasons To Buy Regenxbio Right Now

Mar 19, 2025, 9:15 AM EDT - 4 months ago

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

Mar 13, 2025, 6:44 PM EDT - 5 months ago

REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:05 PM EDT - 5 months ago

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

Mar 10, 2025, 7:05 AM EDT - 5 months ago

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 4, 2025, 7:31 AM EST - 5 months ago

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

Feb 26, 2025, 4:05 PM EST - 5 months ago

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Feb 11, 2025, 3:20 PM EST - 6 months ago

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

Jan 30, 2025, 7:05 AM EST - 6 months ago

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

Jan 16, 2025, 4:01 AM EST - 7 months ago

Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026

AMD

Jan 15, 2025, 3:27 PM EST - 7 months ago

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

Jan 14, 2025, 5:00 AM EST - 7 months ago

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

Jan 13, 2025, 8:31 AM EST - 7 months ago

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

ABBV

Dec 6, 2024, 6:29 PM EST - 8 months ago

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

AMTM APO CMA CRI CRS HPP KELYA

Nov 18, 2024, 7:05 AM EST - 9 months ago

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

Nov 14, 2024, 7:05 AM EST - 9 months ago

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

Nov 6, 2024, 11:16 PM EST - 9 months ago

REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 9 months ago

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

Oct 31, 2024, 3:38 PM EDT - 9 months ago

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Oct 30, 2024, 7:05 AM EDT - 9 months ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

Oct 21, 2024, 7:05 AM EDT - 10 months ago

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024

Oct 18, 2024, 7:05 AM EDT - 10 months ago

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

Sep 23, 2024, 4:05 PM EDT - 11 months ago

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference

Sep 17, 2024, 7:05 AM EDT - 11 months ago

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

Sep 3, 2024, 8:04 AM EDT - 11 months ago

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect

Aug 27, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Aug 8, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 6, 2024, 4:03 PM EDT - 1 year ago

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder

Aug 1, 2024, 11:06 PM EDT - 1 year ago

REGENXBIO Inc. (RGNX) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:05 PM EDT - 1 year ago

REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights

Aug 1, 2024, 7:03 AM EDT - 1 year ago

REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202

Jul 25, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

Jun 24, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients

Jun 18, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

Jun 12, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Announces Leadership Transition

Jun 10, 2024, 11:55 PM EDT - 1 year ago

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

DarkOrb Jul. 31 at 8:36 PM

$RGNX Quarterly call is August 7 premarket. Call info in the link below. https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-host-conference-call-august-7-discuss-second-quarter-0

0 · Reply

maphere Jul. 31 at 5:41 PM

0 · Reply

maphere Jul. 31 at 4:30 PM

1 · Reply

cold_beef_cake Jul. 30 at 7:21 PM

$RGNX Whoa, Vinay Prasad resigned from his position. Didn't realize. That was likely the reason most bios were up close to 10% at one point today.

0 · Reply

NVDAMillionaire Jul. 29 at 10:40 PM

0 · Reply

maphere Jul. 29 at 7:52 PM

2 · Reply

maphere Jul. 29 at 3:07 PM

1 · Reply

maphere Jul. 28 at 2:43 PM

1 · Reply

rando321456 Jul. 25 at 9:34 PM

1 · Reply

DarkOrb Jul. 24 at 7:08 PM

3 · Reply

BioRich Jul. 22 at 5:30 PM

$CLSD Thanks for @maphere for getting us on Clearside's upcoming involvement in the December, '25 Dry AMD conference. Here's a list of Expert Speakers, that included $CLSD, but does not include $RGNX. Is that because they're one and the same by the time of the conference? Probably. Great find @maphere! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI

2 · Reply

Futurision Jul. 20 at 8:57 PM

$SRPT my aggressive take on what the board should do: $SGMO $RGNX $CAPR $VYGR https://x.com/soeren_berlin/status/1947037141478867135?s=46

6 · Reply

DarkOrb Jul. 18 at 6:12 PM

$RGNX Latest SRPT drama is that it's being reported that FDA has requested a complete halt on Elevidys after the report today of another liver failure patient death in a different SRPT program (in clinical trials), which SRPT seemed to hide from investors (the death occurred in June). The other SRPT program uses same AAV as Elevidys. What a mess. https://x.com/adamfeuerstein/status/1946260914505646144

1 · Reply

maphere Jul. 18 at 4:53 PM

$CLSD $RGNX Regenxbio going after Dry AMD via SCS? There's more going on in the background then we're all aware. It's tough to hold but then look at the 1 year chart of $VOR from this year. As low as .17 now at $2.26.

2 · Reply

DarkOrb Jul. 17 at 2:57 AM

$RGNX There was an update after the close today from SRPT on Elevidys following the two liver failure deaths early this year. The FDA requested a black box warning for ambulant patients. And SRPT is working on a protocol change regarding non-ambulant patients. "Consistent with other AAV-delivered gene therapies, the FDA has requested that the label include a black box warning for acute liver injury (ALI) and acute liver failure (ALF). Sarepta agrees with this change, which appears to resolve any material issues with the ambulant portion of the ELEVIDYS label." https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-strategic-restructuring-and

2 · Reply

maphere Jul. 14 at 2:53 PM

$CLSD $RGNX Update on EURETINA: Sept. 3rd is a pre-conference event called Innovation Spotlight https://euretina.org/eis-2025/programme/ Sept. 4-7 is the full program https://euretina.org/paris-2025/programme-overview-list-view/ Searching the program I see no sessions for SCS and RGX-314 but there are a couple for SR delivery for 314. Clearside has 2 presentations, one from Victor (you'll have to use their keyword search, use suprachoroidal: A Decade-Long Review of the Evolution of Suprachoroidal Drug Delivery with a Focus on Axitinib Injectable Suspension for Neovascular Age-Related Macular Degeneration https://euretina.org/paris-2025/programme-overview-list-view/ Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-Related Macular Degeneration: Phase 2b Results from ODYSSEY and Phase 3 Program Update https://euretina.org/paris-2025/programme-overview-list-view/ Biomechanics of Suprachoroidal drug delivery (Dr. Ciulla) https://euretina.org/paris-2025/programme-overview-list-view/

1 · Reply

maphere Jul. 13 at 5:11 PM

$CLSD $RGNX So Euretina in September has a big presentation from ABBV and untitled from RGNX and clsd not listed as presenting... What's happening? https://euretina.org/eis-2025/programme/

1 · Reply

rando321456 Jul. 13 at 1:40 AM

$RGNX Ultragenyx's recent CMC delay from the FDA characterizes the risk around RGX-121's approval abit better imo as it's basically the same type of trial setup and data package. The good thing about it is that the FDA seems to be perfectly fine with the clinical data, however there is the ever present risk of getting the agency to sign off on manufacturing. Hopefully Regenx's preparation pays off in this aspect of approval. Also do we get a cut of the MPS IIIA asset still? It's kind of confusing as it was licensed to an entity that had a legal dispute and the license was terminated, but then the asset was sold to Ultrangenyx who also has a license agreement with Regenx. Would be nice if Regenx still gets a 10-13% cut though.

1 · Reply

maphere Jul. 11 at 4:10 PM

$RGNX I've heard this phrase from Regenxbio a couple times now re: the DR pivotal program: "we are internally excited about..." Is this code for something? I'd much prefer, we and are partner Abbvie are excited about..., seems like they're being careful not to speak for Abbvie as we know ABBV can decide not to move forward with the PH3 for DR, this is why they use the language "planning a PH3". You can listen at the 2:00 minute mark on the Regenxbio video from May 31st hosted on this page, you'll have to "load more options" at the bottom to see it: https://www.eyecelerator.com/park-city-2025-showcases

1 · Reply

rando321456 Jul. 11 at 1:36 PM

$RGNX This a new subretinal phase 3b study? Kind of interesting if so. https://clinicaltrials.gov/study/NCT07007065?term=rgx-314&page=2&rank=11

3 · Reply

WaveRB77 Jul. 10 at 11:46 PM

$RGNX thos company has 3 phase 3 clinical gene therapy drugs that are earth shattering.please tell this stock to run!!@

0 · Reply

maphere Jul. 10 at 6:53 PM

$CLSD $RGNX Regenxbio has a job opening for the following: Device Engineer I/II/III REGENXBIO · 3 months ago · Rockville, Maryland What you'll be doing Contribute to device design and development, Support medical device and combination product development on internal programs and activities with external device suppliers and development partners. Develop and qualify device test methods and author SOPs. Perform drug-device compatibility studies and device safety and functionality testing to support device feasibility studies, engineering assessments, and design veriﬁcation. part of a team responsible for the development of drug delivery systems for (AAV) gene therapy products...support a portfolio containing delivery technologies intended for localized delivery, including ocular and intrathecal routes of administration, and for systemic intravenous delivery. ...you will contribute to device feasibility evaluations, design and development https://www.levels.fyi/jobs?jobId=98371148277785286

2 · Reply

Market Cap	410.81M
Revenue (ttm)	83.33M
Net Income (ttm)	-227.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-272.53%
Debt to Equity Ratio	0.00

Volume	539,900
Avg Vol	886,104
Day's Range	N/A - N/A
Shares Out	50.16M
Stochastic %K	12%
Beta	1.11
Analysts	Strong Sell
Price Target	$31.75